{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-136386","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.776757+00:00","generated_at":"2026-05-29T03:04:20.786898+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD","bullets":["First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.","Voyage study to enroll ~200 participants in US; topline data from 12-week double-blind period expected H1 2026.","Builds on positive Phase 2b study results presented at APA Annual Meeting in May 2024; second Phase 3 Panorama study on track for H1 2025.","MM120 ODT is a pharmaceutically optimized form of LSD; study includes 52-week duration with 40-week open-label extension."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-136386","json":"https://secwatch.observer/filing/0000950170-24-136386.json","markdown":"https://secwatch.observer/filing/0000950170-24-136386.md","text":"https://secwatch.observer/filing/0000950170-24-136386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/0000950170-24-136386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/mnmd-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:04:20.786898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}